CNS Pharmaceuticals (FRA:BE50) Interest Expense: €-0.01 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BE50 CNS Pharmaceuticals Inc FRA:BE50
29 GF Score
Price €0.61
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals Interest Expense?

CNS Pharmaceuticals FRA:BE50 29 Interest Expense is €-0.01 Mil as of Mar. 2026. GuruFocus rates FRA:BE50 with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CNS Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was € -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CNS Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was € -4.30 Mil. CNS Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was € -0.01 Mil. CNS Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CNS Pharmaceuticals  (FRA:BE50) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

CNS Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was €-0.01 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-4.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

CNS Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

CNS Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

CNS Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Interest Expense Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only -0.01 -0.01 -0.01 -0.02 -0.01

CNS Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.00 -0.00 -0.00 -0.01
FRA:BE50
29GF Score
CNS Pharmaceuticals Inc FRA:BE50
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.01 Mil mean?
CNS Pharmaceuticals (FRA:BE50) has a Interest Expense of €-0.01 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on CNS Pharmaceuticals and its competitors.
Is CNS Pharmaceuticals' Interest Expense too high?
CNS Pharmaceuticals' current Interest Expense is €-0.01 Mil. Overall, CNS Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' Interest Expense compare to NXTC and ENVB?
CNS Pharmaceuticals' Interest Expense of €-0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on CNS Pharmaceuticals and its competitors. CNS Pharmaceuticals's current Interest Expense is €-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (FRA:BE50) has a current Interest Expense of €-0.01 Mil. The current Interest Expense is €-0.01 Mil. CNS Pharmaceuticals' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For CNS Pharmaceuticals (FRA:BE50), the current Interest Expense is €-0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Other Exchanges CNSP:USA
Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
29GF Score

Get the complete analysis for FRA:BE50

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price